1. Lin, Yunting, Zeng, Chunhua, Lu, Zhikun, Lin, Ruizhu, Liu, Li. 2019. A novel homozygous splice-site variant of NCAPD2 gene identified in two siblings with primary microcephaly: The second case report. In Clinical genetics, 96, 98-101. doi:10.1111/cge.13559. https://pubmed.ncbi.nlm.nih.gov/31056748/
2. Gu, Jiang-Xue, Huang, Ke, Zhao, Wei-Lin, Huang, Yu-Gang, Hu, Pei. 2024. NCAPD2 augments the tumorigenesis and progression of human liver cancer via the PI3K‑Akt‑mTOR signaling pathway. In International journal of molecular medicine, 54, . doi:10.3892/ijmm.2024.5408. https://pubmed.ncbi.nlm.nih.gov/39092569/
3. He, Jinsong, Gao, Rui, Yang, Jianbo, Zhou, Zihan, Wei, Wei. 2022. NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1. In Cancer science, 114, 896-907. doi:10.1111/cas.15347. https://pubmed.ncbi.nlm.nih.gov/35348268/
4. Li, Zihao, Zheng, Yuxuan, Wu, Zuotao, Wang, Yongyong, Chen, Mingwu. . NCAPD2 is a novel marker for the poor prognosis of lung adenocarcinoma and is associated with immune infiltration and tumor mutational burden. In Medicine, 102, e32686. doi:10.1097/MD.0000000000032686. https://pubmed.ncbi.nlm.nih.gov/36701707/
5. Dong, Xiaoying, Liu, Ting, Li, Zhizhao, Zhai, Yongzhen. 2023. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers. In Aging, 15, 7237-7257. doi:10.18632/aging.204904. https://pubmed.ncbi.nlm.nih.gov/37498296/
6. Ge, Hao, Wang, Can, Zhao, Haoran, Liu, Ping, Yang, Bolin. . Targeting NCAPD2 as a Therapeutic Strategy for Crohn's Disease: Implications for Autophagy and Inflammation. In Inflammatory bowel diseases, 31, 178-188. doi:10.1093/ibd/izae211. https://pubmed.ncbi.nlm.nih.gov/39340820/
7. Zhang, Ping, Liu, Ling, Huang, Jinsha, Xiong, Nian, Wang, Tao. 2014. Non-SMC condensin I complex, subunit D2 gene polymorphisms are associated with Parkinson's disease: a Han Chinese study. In Genome, 57, 253-7. doi:10.1139/gen-2014-0032. https://pubmed.ncbi.nlm.nih.gov/25166511/
8. Ma, Ping, Yu, Huajiao, Zhu, Mingda, Han, Zhengxue, Jin, Wulong. 2024. NCAPD2 promotes the malignant progression of oral squamous cell carcinoma via the Wnt/β-catenin pathway. In Cell cycle (Georgetown, Tex.), 23, 588-601. doi:10.1080/15384101.2024.2348918. https://pubmed.ncbi.nlm.nih.gov/38743408/
9. Wu, Peiling, Zhao, Lifang, Zhang, Hongyan, Liu, Xueqing, Jiang, Handong. 2024. NCAPD2 serves as a potential prognostic biomarker for lung adenocarcinoma and promotes cell proliferation, migration, invasion and cell cycle in vitro. In Oncology research, 32, 1439-1452. doi:10.32604/or.2024.047490. https://pubmed.ncbi.nlm.nih.gov/39220139/
10. Feng, Linyuan, Yang, Yang, Lin, Zhenhua, Jin, Aihua, Cui, Aili. 2024. NCPAD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer. In Genes and environment : the official journal of the Japanese Environmental Mutagen Society, 46, 2. doi:10.1186/s41021-023-00291-4. https://pubmed.ncbi.nlm.nih.gov/38172945/
智鼠故事 
